Evidence map›Paper›PMID 42656497›Full record

SynthesisFrontiers in veterinary science2026

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis.

Yali Chen, Yu Gao, Shumin Li, Bo Liu, Ingo Nolte, Hugo Murua Escobar, Feng Yu

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yali Chen *Department of Small Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Yu Gao *Department of Large Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Shumin Li *Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.
Bo LiuDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Ingo NolteDepartment of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
Hugo Murua EscobarInstitute of Medical Genetics, University Medical Center Rostock, Rostock, Germany.
Feng YuDepartment of Small Animal Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research. Objectives: To systematically evaluate the efficacy of TKIs in the treatment of cL. Methods: A comprehensive search of PubMed, Web of Science, Cochrane, and Embase databases was conducted, encompassing studies published between January 1, 2004 and January 1, 2026, using controlled vocabulary terms including "Canine," "Dogs," "Lymphoma," and "Tyrosine Kinase Inhibitors". A meta-analysis was subsequently performed to evaluate the efficacy of TKIs. Results: Seventeen articles were included, comprising 11 clinical trials and 9 Conclusions: TKIs show moderate therapeutic activity in cL and support the role of dogs as a translational model for NHL research. However, further studies are needed to confirm their efficacy and safety and to explore optimal combination and personalized treatment strategies.

Indexed as

canineclinical trialslymphomameta-analysistyrosine kinase inhibitors

Identifiers

PMID42656497
PMCPMC13506451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.